Trials / Active Not Recruiting
Active Not RecruitingNCT06707883
A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 258 (actual)
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy and safety of TQC2731 injection in patients with moderate to severe chronic obstructive pulmonary disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQC2731 injection | TQC2731 injection is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP) |
| DRUG | TQC2731 Placebo | TQC2731 Placebo without drug substance. |
Timeline
- Start date
- 2024-12-31
- Primary completion
- 2026-12-01
- Completion
- 2027-09-01
- First posted
- 2024-11-27
- Last updated
- 2025-12-12
Locations
60 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06707883. Inclusion in this directory is not an endorsement.